Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection

Abstract Background and Aim Immune checkpoint inhibitors (ICIs) can cause immune‐related adverse events in the liver. The risk of exacerbating liver injury is of concern in patients infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), as immunotherapy can damage liver function because o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tasuku Nakabori, Yutaro Abe, Sena Higashi, Takeru Hirao, Yasuharu Kawamoto, Shingo Maeda, Kazuma Daiku, Makiko Urabe, Yugo Kai, Ryoji Takada, Takuo Yamai, Kenji Ikezawa, Hiroyuki Uehara, Kazuyoshi Ohkawa
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2022-05-01
Schriftenreihe:JGH Open
Schlagworte:
hepatitis B virus
hepatitis C virus
immunotherapy
liver injury
Online Zugang:https://doi.org/10.1002/jgh3.12737
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge